Health Catalyst exec sells $8.7k of company stock By Investing.com

SALT LAKE CITY, UT – In a recent transaction, Linda Llewelyn, the Chief People Officer of Health Catalyst , Inc. (NASDAQ:), sold 1,328 shares of company stock at a price of $6.57 per share, totaling approximately $8,724. The sale took place on August 15, 2024, and was disclosed in a filing with the Securities and Exchange Commission.

Llewelyn’s transaction was executed under a pre-arranged trading plan, known as a 10b5-1 plan, established on May 23, 2023. These plans are commonly used by company insiders to sell a predetermined number of shares at a predetermined time to avoid accusations of insider trading.

Following the sale, Llewelyn still holds a significant stake in the company, with 118,536 shares of Health Catalyst’s common stock remaining in her possession. The transaction reflects a routine sale and is part of the normal course of action for executives managing their personal stock holdings.

Health Catalyst, Inc., headquartered in South Jordan, Utah, is a provider of data and analytics technology and services to healthcare organizations. The company’s stock is publicly traded on the NASDAQ, and it operates under the standard industrial classification of computer programming, data processing, and other related services.

Investors and the market typically monitor insider transactions as they can provide insights into an executive’s view of the company’s future prospects. However, it’s important to note that insider selling does not always indicate a lack of confidence in the company and can be motivated by a variety of personal financial considerations.

In other recent news, Health Catalyst has reported robust Q2 2024 financial results, surpassing guidance. The company’s revenue reached $75.9 million, marking a 4% increase from the previous year, and adjusted EBITDA stood at $7.5 million. Health Catalyst has also seen significant growth in its platform subscription client base, exceeding the total of the previous year within the first half of 2024.

In addition to its financial success, the company has been recognized by Newsweek and Modern Healthcare and has announced strategic partnerships with SingHealth and Adena Health. Health Catalyst has also secured a new credit facility with Silver Point Finance and ended Q2 with $308.1 million in cash.

Despite a client undergoing bankruptcy proceedings, Health Catalyst maintains its full-year adjusted EBITDA guidance. The company is also projecting its full-year 2024 revenue to be between $304 million and $312 million. Looking ahead, Health Catalyst expects to see double-digit revenue growth return in 2025.

InvestingPro Insights

As Health Catalyst, Inc. (NASDAQ:HCAT) continues to navigate the ever-evolving healthcare technology landscape, the recent insider transaction by Linda Llewelyn, the Chief People Officer, has brought some attention to the company’s financial health and future outlook. According to real-time data from InvestingPro, Health Catalyst’s market capitalization stands at approximately $408.78 million, reflecting the size and value of the company in the competitive market.

One notable InvestingPro Tip for Health Catalyst is that the company holds more cash than debt on its balance sheet, which could be indicative of financial stability and the ability to invest in growth opportunities or weather economic downturns. Additionally, analysts have predicted that Health Catalyst will become profitable this year, which may signal a positive shift in the company’s financial trajectory.

From a data perspective, Health Catalyst has shown a revenue growth of 5.23% over the last twelve months as of Q2 2024, demonstrating its ability to increase earnings. However, it’s important to note that the company’s P/E ratio is currently negative at -4.56, and the adjusted P/E ratio for the last twelve months as of Q2 2024 is also negative at -6.02, highlighting that the company is not currently profitable. This aligns with another InvestingPro Tip that Health Catalyst has not been profitable over the last twelve months.

For investors looking to delve deeper into the financials and future projections of Health Catalyst, there are additional InvestingPro Tips available on the platform. For instance, while 4 analysts have revised their earnings downwards for the upcoming period, the platform lists a total of 6 tips that can provide a more comprehensive understanding of Health Catalyst’s potential and challenges.

For a more detailed analysis and to explore the full range of InvestingPro Tips for Health Catalyst, interested parties can visit https://www.investing.com/pro/HCAT. The insights offered there could be particularly valuable for investors considering the implications of insider transactions like that of Llewelyn’s recent stock sale.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.